The Baruch et al., study demonstrated that a combination of FMT from a donor who displayed a complete response to immunotherapy, and the re-introduction of anti-PD-1 therapy in refractory metastatic melanoma patients was safe, feasible and potentially effective. This evidence concerns the gene PDCD1 and metastatic melanoma.